Literature DB >> 34735869

Circulating C1q levels in health and disease, more than just a biomarker.

Fleur S van de Bovenkamp1, Douwe J Dijkstra1, Cees van Kooten2, Kyra A Gelderman3, Leendert A Trouw4.   

Abstract

C1q is the recognition molecule of the classical pathway of the complement system. By binding to its targets, such as antigen-bound immunoglobulins or C-reactive protein, C1q contributes to the innate defense against infections. However, C1q also plays several other roles beyond its traditional role in complement activation. Circulating levels of C1q are determined in routine diagnostics as biomarker in several diseases. Decreased C1q levels are present in several autoimmune conditions. The decreased levels reflect the consumption of C1q by complement activation and serves as a biomarker for disease activity. In contrast, increased C1q levels are present in infectious and inflammatory diseases and may serve as a diagnostic biomarker. The increased levels of C1q are still incompletely understood but are suggested to modulate the adaptive immune response as C1q is known to impact on the maturation status of antigen-presenting cells and C1q impacts directly on T cells leading to decreased T-cell activity in high C1q conditions. In this review, we provide a comprehensive overview of the current literature on circulating levels of C1q in health and disease, and discuss how C1q can both protect against infections as well as maintain tolerance by regulating adaptive immunity.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adaptive immunity; Biomarker; C1q; Classical pathway; Complement system; Tolerance

Mesh:

Substances:

Year:  2021        PMID: 34735869     DOI: 10.1016/j.molimm.2021.10.010

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  [Proteomics of serum exosomes in children in the acute stage of Kawasaki disease: a prospective study].

Authors:  Fan Zhang; Qian-Wen Zhang; Na-Na Wang; Qian Liu; Jie Shen; Miao Hou; Ling Sun; Hai-Tao Lyu; Wen-Hua Yan; Jie Huang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

2.  Association of C1q gene cluster variants with rheumatoid arthritis: a pilot study.

Authors:  Mariya Blagoeva Kosturkova; Galya Mihaylova Mihaylova; Tanya Kirilova Shivacheva; Maria Atanasova Radanova
Journal:  Rheumatol Int       Date:  2022-01-13       Impact factor: 2.631

Review 3.  Understanding the contextual functions of C1q and LAIR-1 and their applications.

Authors:  Myoungsun Son
Journal:  Exp Mol Med       Date:  2022-05-13       Impact factor: 12.153

4.  Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia.

Authors:  Douwe Jan Dijkstra; A Inkeri Lokki; Lobke Marijn Gierman; Nicole Veronique Borggreven; Carin van der Keur; Michael Eikmans; Kyra Andrea Gelderman; Hannele Laivuori; Ann-Charlotte Iversen; Marie-Louise P van der Hoorn; Leendert Adrianus Trouw
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

5.  Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.

Authors:  Zehao Zhao; Meishi Ma; Xin Huang; Tienan Sun; Kangning Han; Shiwei Yang; Yujie Zhou
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

Review 6.  The Potential Roles of Extracellular Vesicles as Biomarkers for Parkinson's Disease: A Systematic Review.

Authors:  Jessica Valencia; Marta Ferreira; J Francisco Merino-Torres; Antonio Marcilla; Jose M Soriano
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.